Kerry L. Reynolds

Statistics

Publications

115

Citations

11.6K

H-Index

Active since

1989

Affiliations

Massachusetts General Hospital(Current)

Harvard University

Brigham and Women's Hospital

Dana-Farber Cancer Institute

Memorial Sloan Kettering Cancer Center

Kerry L. Reynolds is an author at Massachusetts General Hospital specializing in immunotherapy, checkpoint inhibitor therapy, and immune checkpoint inhibitors.

ORCID

Publications per year

1989–2025

115

Publications

115

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Nicole M. Kuderer, Toni K. Choueiri, Dimpy P. Shah et al. · The Lancet · 2020 · 1.8K citations · Full text

Medicine, Clinical Sciences, Oncology +8

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors

Syed Mahmood, Michael G. Fradley, Justine V. Cohen et al. · Journal of the American College of Cardiology · 2018 · 1.5K citations · Full text

Life Sciences, Immunology, Internal Medicine +12

Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement

Joerg Herrmann, Daniel J. Lenihan, Saro H. Armenian et al. · European Heart Journal · 2021 · 595 citations · Full text

Medicine, Cardiology, Oncology +16

Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque

Zsófia D. Drobni, Raza M. Alvi, Jana Taron et al. · Circulation · 2020 · 537 citations · Full text

Life Sciences, Immunology, Oncology +14

Clinical Features and Outcomes of Immune Checkpoint Inhibitor–Associated AKI: A Multicenter Study

Frank B. Cortazar, Zoé A. Kibbelaar, Ilya Glezerman et al. · Journal of the American Society of Nephrology · 2020 · 388 citations · Full text

Medicine, Immunology, Nephrology +14

1–5 of 115